Sorrento Therapeutics, Inc.
Other OTCTotal Valuation
Sorrento Therapeutics, Inc. carries a market capitalization of 303,205.00, placing it among publicly traded companies globally. Its enterprise value stands at 134.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 303,205.00 |
| Enterprise Value | 134.12M |
Share Statistics
Sorrento Therapeutics, Inc. currently has 551.28M shares outstanding.
| Shares Outstanding | 551.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 2.09 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Sorrento Therapeutics, Inc. maintains a current ratio of 0.50, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -104.87, indicating conservative leverage, while an interest coverage ratio of -50.15 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.50 |
| Quick Ratio | 0.43 |
| Debt / Equity | -104.87 |
| Debt / EBITDA | -0.61 |
| Interest Coverage | -50.15 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -100.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.35 |
Taxes
| Income Tax | 9.31M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Sorrento Therapeutics, Inc.'s stock has declined approximately -57.69231% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -57.69231% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sorrento Therapeutics, Inc. generated 64.27M in revenue and converted that into -548.10M in net income, yielding earnings per share of -1.13. EBITDA reached -341.59M, while operating income came in at -355.52M.
| Revenue | 64.27M |
| Gross Profit | 28.64M |
| Operating Income | -355.52M |
| Pretax Income | -552.86M |
| Net Income | -548.10M |
| EBITDA | -341.59M |
| EBIT | -355.52M |
| Earnings Per Share (EPS) | -1.13 |
Balance Sheet
Sorrento Therapeutics, Inc. holds 80.64M in cash and equivalents against 207.60M in total debt, resulting in a net debt position of 72.35M. Total book value stands at -2.19B, with working capital of -131.84M providing operational flexibility.
| Cash & Cash Equivalents | 80.64M |
| Total Debt | 207.60M |
| Net Debt | 72.35M |
| Equity (Book Value) | -2.19B |
| Book Value Per Share | -4.26 |
| Working Capital | -131.84M |
Cash Flow
Sorrento Therapeutics, Inc. produced -234.63M in operating cash flow over the past twelve months. After subtracting -8.58M in capital expenditures, free cash flow totaled -243.21M - equivalent to -0.47 per share.
| Operating Cash Flow | -234.63M |
| Capital Expenditures | -8.58M |
| Free Cash Flow | -243.21M |
| FCF Per Share | -0.47 |
Margins
Sorrento Therapeutics, Inc. operates with a gross margin of 44.56, reflecting its pricing power and cost economics. The operating margin of -553.17 and net profit margin of -852.80 provide insight into operational efficiency.
| Gross Margin | 44.56 |
| Operating Margin | -553.17 |
| Pretax Margin | -860.21 |
| Profit Margin | -852.80 |
| EBITDA Margin | -531.50 |
Stock Splits
Sorrento Therapeutics, Inc.'s most recent stock split took place on August 1, 2013 with a 25:1 split ratio.
| Last Split Date | 8/1/2013 |
| Split Ratio | 25:1 |
Scores
Sorrento Therapeutics, Inc. posts an Altman Z-Score of -17.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -17.07 |